Reparaturwege in Krebszellen gezielt ausschalten
Open Access
- 28 March 2022
- journal article
- research article
- Published by Springer Nature in BIOspektrum
- Vol. 28 (2) , 159-161
Abstract
Mutations in BRCA1 or BRCA2 are associated with breast, ovarian and other cancers. Cells with these mutations are defective in homologous recombination (HR), one of two main processes to repair DNA double-strand breaks (DSBs). Survival of these cells strongly relies on the usage of alternative repair pathways, such as POLθ-mediated end-joining (TMEJ). Thus, targeting TMEJ could be a promising new strategy for the therapy of BRCA1- and BRCA2-mutant tumours.Keywords
This publication has 7 references indexed in Scilit:
- POLθ-mediated end joining is restricted by RAD52 and BRCA2 until the onset of mitosisNature Cell Biology, 2021
- One end to rule them all: Non-homologous end-joining and homologous recombination at DNA double-strand breaksBritish Journal of Radiology, 2020
- Beyond PARP—POLθ as an anticancer targetScience, 2018
- Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitorsNucleic Acids Research, 2016
- Homologous-recombination-deficient tumours are dependent on Polθ-mediated repairNature, 2015
- Mammalian polymerase θ promotes alternative NHEJ and suppresses recombinationNature, 2015
- BRCA1 and BRCA2: different roles in a common pathway of genome protectionNature Reviews Cancer, 2011